Quantcast

Latest Tardive dyskinesia Stories

2011-06-23 07:30:00

SAN DIEGO, June 23, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the Company's proprietary Vesicular Monoamine Transporter 2 inhibitor (VMAT2), NBI-98854. The Notice of Allowance indicates that a composition of matter patent on NBI-98854 will have an initial patent term extending to May 2029. Additionally, on June 17, 2011, the Company held a...

2011-04-13 07:42:03

(Ivanhoe Newswire) -- Results of the first, long-term clinical trial show the investigational drug safinamide may reduce dyskinesia (involuntary movements) in mid-to-late stage Parkinson's disease. "Our findings over a two-year treatment period suggest that taking safinamide in addition to levodopa and other dopaminergic treatments could help patients who continue to experience tremors and involuntary movement problems," study author Ravi Anand, M.D., a consultant with Newron Pharmaceuticals...

2011-04-12 15:01:21

Results of the first randomized, placebo-controlled long-term clinical trial show the investigational drug safinamide may reduce dyskinesia or involuntary movements in mid-to-late stage Parkinson's disease. The findings will be presented as late-breaking research at the 63rd Annual Meeting of the American Academy of Neurology, April 9, 2011, in Honolulu. "Our findings over a two-year treatment period suggest that taking safinamide in addition to levodopa and other dopaminergic treatments...

2011-04-11 07:00:00

TITUSVILLE, N.J., April 11, 2011 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) on April 6 approved INVEGA® (paliperidone) extended-release tablets for the treatment of schizophrenia in adolescents 12 to 17 years of age. The efficacy of INVEGA® to treat schizophrenia in adolescents was established in one six-week clinical study. INVEGA® is an atypical antipsychotic medication and was first approved in the U.S. in December...

2011-04-05 08:00:00

SAN DIEGO, April 5, 2011 /PRNewswire/ --Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has completed the dosing and preliminary assessment of the initial cohort of Tardive Dyskinesia patients using its proprietary Vesicular Monoamine Transporter 2 inhibitor (VMAT2), NBI-98854. Based on this data, the Company is initiating the Investigational New Drug (IND) application process with the U.S. Food and Drug Administration (FDA). "We are very pleased with these preliminary...

2010-12-01 08:00:00

COMMACK, N.Y., Dec. 1, 2010 /PRNewswire/ -- The law office of Rudolph F.X. Migliore, P.C. announced today the firm is now accepting cases on behalf of people who used the prescription drug Reglan and later developed tardive dyskinesia, a neurological disorder that causes uncontrollable, repetitive movements of the body, such as grimacing, lip smacking, eye blinking or rapid leg and arm movements. The symptoms are rarely reversible and there is no known treatment. "Millions of Americans...

2010-10-18 07:00:00

SAN DIEGO, Oct. 18 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has successfully completed a second Phase I clinical trial of its proprietary Vesicular Mono-Amine Transporter 2 compound, NBI-98854. The positive results of this Phase I study of repeated dosing in healthy volunteers allows the VMAT2 program to initiate Phase II studies. "Our VMAT2 inhibitor was well tolerated and again showed us the desired pharmacokinetic and safety...

2010-07-19 17:01:00

ATLANTA, July 19 /PRNewswire/ -- The law firm of Childers, Schlueter & Smith, LLC of Atlanta, Georgia has announced that a jury trial involving the drug Reglan/metoclopramide will be held during the week of July 26, 2010. The case is Susan Swicegood v. Pliva et. al. in the United States District Court, Northern District of Georgia, Atlanta Division. The lawsuit alleges that the drug makers and marketers of Reglan/metoclopramide failed to adequately warn physicians of the long-term...

2010-05-03 11:59:00

Reglan, metoclopramide never approved for use in infants HOUSTON, May 3 /PRNewswire-USNewswire/ -- Recently, researchers have observed a disturbing trend in neonatal units across the country: doctors prescribing Reglan -- also known by its generic name, metoclopramide -- to treat premature infants. This alarming development has raised serious concerns from many consumer safety advocates, particularly because the drug was never approved for use in infants. Reglan (metoclopramide) was...

2010-04-13 15:15:00

SAN DIEGO, April 13 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has received approval from Health Canada to commence its second Phase I clinical trial of its proprietary Vesicular Mono-Amine Transporter 2 compound, NBI-98854. "We are looking forward to starting our Phase I multiple repeated dose study of VMAT2 this month," said Christopher F. O'Brien, Chief Medical Officer of Neurocrine Biosciences. "Our VMAT2 inhibitor was well tolerated...


Word of the Day
reremouse
  • A bat.
The word 'reremouse' comes from Middle English reremous, from Old English hrēremūs, hrērmūs ("bat"), equivalent to rear (“to move, shake, stir”) +‎ mouse.
Related